. 2017 Jun 1;28(5):e62. doi: 10.3802/jgo.2017.28.e62

Table 2. Prognostic impact of clinical pathological factors using the log-rank test.

Variables	Subsets	No.	p-value
Variables	Subsets	No.	PFS	OS
FIGO stage	I–II	18	0.013^*	0.022^*
FIGO stage	III–IV	11	0.013^*	0.022^*
Carcinomatous component	Endometrioid	12	0.504	0.263
Carcinomatous component	Others	16	0.504	0.263
Carcinoma grade	G1–2	7	0.003^*	0.021^*
Carcinoma grade	G3	21	0.003^*	0.021^*
Sarcomatous component	Homologous	17	0.181	0.117
Sarcomatous component	Heterologous	10	0.181	0.117
Tumor size (cm)	<7	13	0.046^*	0.128
Tumor size (cm)	≥7	15	0.046^*	0.128
Myometrial invasion	≤1/2	15	0.174	0.596
Myometrial invasion	>1/2	13	0.174	0.596
LVSI	Yes	12	0.600	0.825
LVSI	No	16	0.600	0.825
Ascites assessment	Positive	8	0.029^*	0.042^*
Ascites assessment	Negative	19	0.029^*	0.042^*
LN metastasis	Positive	4	<0.001^*	0.002^*
LN metastasis	Negative	21	<0.001^*	0.002^*
Pathological necrosis	Present	15	0.672	0.704
Pathological necrosis	Absent	6	0.672	0.704
MRI unenhanced region (%)	<10	9	0.143	0.019^*
MRI unenhanced region (%)	≥10	13	0.143	0.019^*

Endometrioid, endometrioid adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; LVSI, lymphovascular space invasion; MRI, magnetic resonance imaging; OS, overall survival; PFS, progression-free survival.

^*p<0.050.